Assay Challenges for Emerging Infectious Diseases: The Zika Experience
AbstractFrom the perspective of vaccine development, it is imperative to accurately diagnose target infections in order to exclude subjects with prior exposure from evaluations of vaccine effectiveness, to track incident infection during the course of a clinical trial and to differentiate immune reactions due to natural infections from responses that are vaccine related. When vaccine development is accelerated to a rapid pace in response to emerging infectious disease threats, the challenges to develop such diagnostic tools is even greater. This was observed through the recent expansion of Zika virus infections into the Western Hemisphere in 2014–2017. When initial Zika vaccine clinical trials were being designed and launched in response to the outbreak, there were no standardized sets of viral and immunological assays, and no approved diagnostic tests for Zika virus infection. The diagnosis of Zika virus infection is still an area of active research and development on many fronts. Here we review emerging infectious disease vaccine clinical assay development and trial execution with a special focus on the state of Zika virus clinical assays and diagnostics. View Full-Text
Share & Cite This Article
Roberts, C.C.; Maslow, J.N. Assay Challenges for Emerging Infectious Diseases: The Zika Experience. Vaccines 2018, 6, 70.
Roberts CC, Maslow JN. Assay Challenges for Emerging Infectious Diseases: The Zika Experience. Vaccines. 2018; 6(4):70.Chicago/Turabian Style
Roberts, Christine C.; Maslow, Joel N. 2018. "Assay Challenges for Emerging Infectious Diseases: The Zika Experience." Vaccines 6, no. 4: 70.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.